Long-term efficacy and safety of ravulizumab in adults with AChR-Ab plus gMG: final results from the phase 3 CHAMPION MG open-label extension

被引：0
|
作者：
Vu, T. [1 ]
Mantegazza, R. [2 ]
Annane, D. [3 ]
Katsuno, M. [4 ]
Meisel, A. [5 ]
Nicolle, M. [6 ]
Bril, V. [7 ]
Aguzzi, R. [8 ]
Frick, G. [8 ]
Howard, J., Jr. [9 ]
机构：
[1] Univ S Florida, Morsani Coll Med, Tampa, FL 33620 USA
[2] Fdn IRCCS Ist Neurol Carlo Besta, Milan, Italy
[3] Hop Raymond Poincare, Garches, France
[4] Nagoya Univ, Grad Sch Med, Nagoya, Aichi, Japan
[5] Charite Univ Med Berlin, Berlin, Germany
[6] London Hlth Sci Ctr, London, ON, Canada
[7] Univ Toronto, Univ Hlth Network, Ellen & Martin Prosserman Ctr Neuromuscular Dis, Toronto, ON, Canada
[8] Alexion, AstraZeneca Rare Dis, Boston, MA USA
[9] Univ N Carolina, Chapel Hill, NC 27515 USA
来源：
NEUROMUSCULAR DISORDERS | 2024年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
506VP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension
    Thaci, Diamant
    Puig, Luis
    Merola, Joseph F.
    Jullien, Denis
    Costanzo, Antonio
    Wang, Maggie
    Deherder, Delphine
    Lopez Pinto, Jose M.
    Lebwohl, Mark
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4733 - 4735
  • [32] Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
    Jürgen Wollenhaupt
    Eun-Bong Lee
    Jeffrey R. Curtis
    Joel Silverfield
    Ketti Terry
    Koshika Soma
    Chris Mojcik
    Ryan DeMasi
    Sander Strengholt
    Kenneth Kwok
    Irina Lazariciu
    Lisy Wang
    Stanley Cohen
    Arthritis Research & Therapy, 21
  • [33] Long-term safety and efficacy of lanreotide treatment in Japanese patients with neuroendocrine tumors: Final analysis of a phase II open-label extension study
    Ito, Tetsuhide
    Hisamatsu, Seiichi
    Nakajima, Akihiro
    Shimatsu, Akira
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [34] Long-Term, Open-Label Safety and Efficacy of Atomoxetine in Adults With ADHD Final Report of a 4-Year Study
    Adler, Lenard A.
    Spencer, Thomas J.
    Williams, David W.
    Moore, Rodney J.
    Michelson, David
    JOURNAL OF ATTENTION DISORDERS, 2008, 12 (03) : 248 - 253
  • [35] Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA-3 trial
    Gooderham, Melinda
    Molin, Sonja
    Bissonnette, Robert
    Worm, Margitta
    Crepy, Marie-Noelle
    Stingeni, Luca
    Warren, Richard B.
    Schliemann, Sibylle
    Balita-Crisostomo, Cherry Lou
    Oesterdal, Marie Louise
    Agner, Tove
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 35 - 36
  • [36] Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata: interim results from the ALLEGRO-LT phase 3, open-label study
    Tsianakas, Athanasios
    Sinclair, Rodney
    Lesiak, Aleksandra
    Mehlis, Stephanie
    Kinoshita-Ise, Misaki
    Arenberger, Petr
    Tziotzios, Christos
    Zhang, Fan
    Law, Ernest
    Lejeune, Alexandre
    Wolk, Robert
    Woodworth, Deborah
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 125 - 126
  • [37] Long-term efficacy and safery of switching from Ustekinumab to Risankizuman: results from the open-label extension LIMMitless
    Strober, Bruce
    Eyerich, Killian
    Hong, H. Chih-Ho
    Zeng, Jiewei
    Valdecantos, Wendell C.
    Valdes, Joaquin
    Bachelez, Herve
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 19 - 19
  • [38] Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension
    Habib, Ali A.
    Druzdz, Artur
    Grosskreutz, Julian
    Mantegazza, Renato
    Sacconi, Sabrina
    Utsugisawa, Kimiaki
    Vu, Tuan
    Vissing, John
    Gayfieva, Maryam
    Pulido-Valdeolivas, Irene
    Tarancon, Thais
    Woltering, Franz
    Bril, Vera
    JOURNAL OF NEUROMUSCULAR DISEASES, 2025,
  • [39] Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study
    Feldt-Rasmussen, Ulla
    Hughes, Derralynn
    Sunder-Plassmann, Gere
    Shankar, Suma
    Nedd, Khan
    Olivotto, Iacopo
    Ortiz, Damara
    Ohashi, Toya
    Hamazaki, Takashi
    Skuban, Nina
    Yu, Julie
    Barth, Jay A.
    Nicholls, Kathleen
    MOLECULAR GENETICS AND METABOLISM, 2020, 131 (1-2) : 219 - 228
  • [40] Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety
    Campbell, Kirk N.
    Gesualdo, Loreto
    Murphy, Edward
    Rheault, Michelle N.
    Srivastava, Tarak
    Tesar, Vladimir
    Komers, Radko
    Trachtman, Howard
    KIDNEY MEDICINE, 2024, 6 (06)
12345